Tonmya is the first new fibromyalgia therapy approved in over 15 years, targeting nonrestorative sleep to alleviate core ...

NIH's new strategy emphasizes transparency, prioritizes urgent health needs, and shifts focus to domestic research and ...

Vanda Pharmaceuticals won a legal battle as a federal court overturned the FDA's rejection of Hetlioz for jet lag disorder, ...

Expanded approval of Wegovy was based on results from the Phase III ESSENCE trial (NCT04822181), which demonstrated ...

What is MFN in pharma? President Trump’s executive order on drug pricing states that the United States should be treated as a ...

How a layered approach—tapping new avenues from earned media—can go a long way in boosting the brand engagement interplay ...

An examination of proactive preparedness and readiness review for future enrollment in the agency’s QMM program—now in the ...

As global director of healthcare and sciences at Google Cloud, Shweta Maniar is working with organizations to find ways to ...

Pfizer's inclacumab fails Phase III study for sickle cell disease, disappointing the community while the company remains ...

Challenging six misconceptions that have characterized product strategies in Central and Eastern European markets.

The report details the administration’s potential plans for a variety of issues that will directly impact pharma.

Health plans face challenges in risk arrangements for orphan drugs, but increasing competition may open doors for innovative ...